Decreased fracture rate by mandating bone protecting agents in the EORTC 1333/PEACEIII trial combining Ra223 with enzalutamide versus enzalutamide alone: An updated safety analysis.

被引：32

作者：

Gillessen, Silke

Choudhury, Ananya

Rodriguez-Vida, Alejo

Nole, Franco

Diaz, Enrique Gallardo

Roumeguere, Thierry Andre

Daugaard, Gedske

Loriot, Yohann

Saad, Fred

McDermott, Raymond S.

Neven, Anouk

Fournier, Beatrice

Tombal, Bertrand F.

机构：

[1] Kantonsspital St Gallen, St Gallen, Switzerland

[2] Christie NHS Fdn Trust, Manchester, Lancs, England

[3] Univ Manchester, Manchester, Lancs, England

[4] Hosp del Mar Res Inst, Dept Med Oncol, Barcelona, Spain

[5] European Inst Oncol, Med Oncol Div Urogenital & Head & Neck Tumors, Milan, Italy

[6] Autonomous Univ Barcelona, Parc Tauli Univ Hosp, Parc Tauli Inst Res & Innovat I3PT, Sabadell, Spain

[7] Univ Clin Brussels, Erasme Hosp, Brussels, Belgium

[8] Copenhagen Univ Hosp, Rigshosp, Copenhagen, Denmark

[9] Univ Paris Saclay, Gustave Roussy, Dept Canc Med, Villejuif, France

[10] Ctr Hosp Univ Montreal, Montreal, PQ, Canada

[11] St Vincents Univ Hosp, Dublin, Ireland

[12] European Org Res Treatment Canc, Brussels, Belgium

[13] EORTC, Brussels, Belgium

[14] Catholic Univ Louvain, Inst Rech Clin, Louvain, Belgium

来源：

关键词：

D O I：

10.1200/JCO.2021.39.15_suppl.5002

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

5002

引用

页数：3